News | Cardiovascular Surgery | October 23, 2019

Michigan Hospital Improves Post-CABG Outcomes Using Proactive Amiodarone Protocol

New research in AACN Advanced Critical Care finds using amiodarone as a prophylaxis after coronary artery bypass graft surgery reduced incidence of postoperative atrial fibrillation

Michigan Hospital Improves Post-CABG Outcomes Using Proactive Amiodarone Protocol

October 23, 2019 — Proactive administration of amiodarone to patients recovering from a common heart surgery shows promise in preventing postoperative atrial fibrillation, a serious and expensive complication with potential long-term consequences.

Reducing New-Onset Atrial Fibrillation After Coronary Artery Bypass Graft Surgery” discusses how Beaumont Hospital, Dearborn, Mich., developed and implemented an evidence-based protocol to use amiodarone as a prophylaxis after coronary artery bypass graft (CABG) surgery. The article is published in AACN Advanced Critical Care.[1]

The quality improvement project resulted in a decreased incidence of postoperative atrial fibrillation (POAF) (17 percent versus 25 percent) and shorter mean lengths of stay. The results indicate that the protocol could significantly reduce costs, improve patient outcomes and increase the overall quality of care.

POAF is the most common dysrhythmia to occur after CABG surgery, affecting 10-40 percent of patients. At Beaumont, nearly a quarter of patients with CABG developed POAF in 2016 and during a six-month period in 2017, establishing a baseline for the study.  

Co-author Melanie Coletta, DNP, CCRN, AGACNP-BC, is a cardiothoracic nurse practitioner at the hospital. The multidisciplinary research team also included the chief of cardiac and thoracic surgery and a cardiology clinical pharmacist specialist, as well as faculty from the nurse practitioner program at the College of Nursing and Health at nearby Madonna University.

“Prior to the protocol, we administered amiodarone reactively to treat POAF, rather than proactively to prevent it,” she said. “We’re continuing to assess and adjust the protocol to improve patient outcomes and generate additional data to support a potential clinical practice guideline specific to the prevention of POAF in the cardiac surgical patient population.”

After an extensive literature review, the research team collaborated to develop an amiodarone POAF prophylaxis protocol, including determining which patients met the inclusion criteria, medication administration and dosing strategy. An order set for the protocol was then created and embedded into the electronic health record as part of the cardiac surgery postoperative order set.

A total of 68 CABG surgeries were performed from Nov. 1, 2017, to Feb. 15, 2018. After exclusions, 47 patients completed the protocol and were included in the statistical analysis. 

Eight of the patients receiving amiodarone prophylaxis (17 percent) developed POAF, and none of them were readmitted with dysrhythmia within 30 days of discharge. In addition, the mean length of stay for the entire study group was six days, which falls within the CABG reimbursement time frame of seven days. In the 2017 baseline group, the mean length of stay was seven days for patients without POAF and eight days for those who developed it.

The article is part of a symposium published in the fall 2019 issue of the peer-reviewed journal that focuses on the positives and negatives of medications in critical care.

Mary Fran Tracy, Ph.D., RN, APRN, CCNS, served as editor for the symposium. She is associate professor, University of Minnesota (UM) School of Nursing, and nurse scientist at UM Medical Center.

“Medications are powerful tools in the arsenal for patient care, especially in critical care, but they can be both friend and foe,” she said. “We are gaining ever-advancing knowledge related to new and traditional drugs, as well as increased understanding of how individuals respond to medications with both appropriate and illicit use.”

For more information: www.acc.aacnjournals.org

Reference

1. Coletta M.J., Lis G., Clark P., et al. Reducing New-Onset Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. AACN Advanced Critical Care, published online Fall 2019. doi: 10.4037/aacnacc2019470

Related Content

Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...